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Before it exerts its biological action on its target tissues, the
circulating form of vitamin D, 25-hydroxyvitamin D (25(OH)D),
must be metabolized primarily by the kidney either to I a,25-
dihydroxyvitarnin D (1 ,25(OH)2D) or 24,25-hydroxyvitamin D
(24,25(OH)2D) by the enzymes 25(OH)D-lct-hydroxylase (1-
hydroxylase) or 25(OH)D-24-hydroxylase (24-hydroxylase), re-
spectively. Activities of these two enzymes are under tight
hormonal and ionic control and there is, in general, a reciprocal
change in activities of the two enzymes: When the 1-hydrox-
ylase activity is stimulated, the 24-hydroxylase activity is
suppressed and vice versa [1—3]. In this article we briefly review
recent advances in the unique hormonal regulation of 1-hydrox-
ylase and 24-hydroxylase and present the concept of two
distinct 1-hydroxylase systems in the mammalian kidney. It has
been appreciated that the kidney is among the target organs for
vitamin D as well as an endocrine organ. Therefore, we include
recent advances in this area including phosphorus and calcium
handling by the kidney, localization of enzymes induced by
1,25(OH)2D3 along the nephron, that is, calcium binding protein
and 24-hydroxylase, the receptors for l,25(OH)2D, and the
proposed mechanisms of vitamin D action, Readers should
refer to recent and, in our opinion, excellent review articles for
broader aspects of vitamin D metabolism and action [1—41.
Localization of 1-hydroxylase
It has been well established that the site of 1-hydroxylase
activity in the kidney is probably the proximal tubules [5, 6].
Indirect immunofluorescence studies show that cytochrome
P-450-dependent mono-oxygenese, the enzyme thought to pos-
sess 1-hydroxylase activity, is localized predominantly in the
proximal convoluted tubules as well as in the glomeruli [7].
Precise localization of l-hydroxylase in the kidney was first
presented by Brunette et al [8] using microdissected single
nephron segments of vitamin D-deficient chick kidney: Signifi-
cant enzyme activity was found only in the proximal convoluted
tubules (PCT) and cortical thick loops, an extention of the PCT.
In contrast to the relative ease of measuring 1-hydroxylase
activity in vitro using various preparations of chick kidney, for
example, homogenates, isolated mitochondria, dispersed tubule
fragments, and so forth, it has been difficult to measure in vitro
the enzyme activity of the mammalian kidney until recently
perhaps because of inhibitors in the in vitro preparations of
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mammalian kidney [9]. After discovering that 1-hydroxylase
activity could be measured in vitro in the homogenate of the
fetal rabbit kidney [10], Akiba et al [11] demonstrated that
1-hydroxylase is localized in both PCT and the proximal
straight tubules (PST) dissected from the fetal rabbit kidney.
Using a similar preparation of dissected tubule segments, we
demonstrated that the 1-hydroxylase is localized only in the
PCT of vitamin D-deficient rat [12, 13]. It is of note that all the
factors known to regulate 1-hydroxylase activity favor stimula-
tion of the enzyme in vitamin D deficiency, for example, high
parathyroid hormone (PTH) level, low endogenous
1 ,25(OH)2D, low plasma concentrations of calcium and inor-
ganic phosphate Pi ions [1—4]. Thus, one can assume that
nephron segments other than the PCT do not possess any
significant 1-hydroxylase activity in vitamin D deficient rats.
Peterson, Ghazarian, and Garancis [14] showed that 1-hy-
droxylase is localized in the nuclear preparation of the
glomeruli and the mitochondria preparation of the proximal
tubule fragments of vitamin D-deficient chick kidney. However,
we with Torikai [13] as well as Akiba et al [11] and Brunette
(personal communication) could not detect any significant en-
zyme activity in the glomeruli. The reasons for these seemingly
discrepant results are not clear. It should be noted, however,
that while the enzyme activities in the proximal tubules re-
ported by Brunette et al [8], Akiba et al[11], and ourselves with
Torikai [13] are comparable, the activity reported by Peterson,
Ghazarian, and Garancis [14] are roughly two orders of magni-
tude lower as summarized in Table 1.
Localization of 24-hydroxylase in the kidney
In many ways the 24-hydroxylation reaction resembles 1-
hydroxylation. Both require molecular oxygen, an atom of
which is incorporated either in the 1- or 24-hydroxyl group [15].
Reduced NADP can be met equally by succinate, malate, or
isocitrate oxidation by the mitochondria. Like 1-hydroxylase,
addition of Pi (3 to 10 mM) tends to stimulate 24-hydroxylase
whereas 1.0 mivi Ca2 is inhibitory [15]. Although isolation of
24-hydroxylase enzyme has, to our knowledge, not yet been
reported, these properties of 24-hydroxylase suggest that it is
probably a cytochrome P-450 enzyme like 1-hydroxylase.
Based on these similarities of the two enzymes and the data that
total P-450 concentration in the kidney does not change with
vitamin D status in animals, Ghazarian [16] suggested the two
distinct hydroxylation reactions might be catalyzed by a single
enzyme system. Using an indirect immunofluorescence tech-
nique, he shows the predominant localization of ferredoxin, a
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Animals
Location of
enzyme activity
Enzyme activitya
fmoles/
mm/hr
fmoles/p.g
protein/hr
Refer-
ences
Rat PCT
PST
0.65 0.08
0.69 0.09
—
—
12, 41
Rabbit
(fetus)
PCT
PST
0.85 0.42
2.52 1.03
3.67 1.83
12.5 5.10
11
Chick PCT
Cortical thick
loop
1.76 0.19
1.73 0.33
12.3 1.4
12.4 2.4
8
Chick Glomerulus
PCT
o12b
07b
14
Abbreviations: PCT, proximal convoluted tubules; PST, proximal
straight tubules.
Values are mean SEM.
b Values are expressed in [141 as 0.12 and 0.17 pmoles/mg protein/hr,
respectively.
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Fig. 1. Effect and time course of TPTX and administration of PTH or
cyclic AMP on the in vivo conversion of 3H-25(OH)D3 to 3H-
1,25(OH)2D3 in vitamin D-deficient rats. The conversion rate was
maximum at the doses of PTH and cyclic AMP given, 7.5 U/hr and 2
u/mole/hr, respectively. (Reproduced from [21] with permission.)
Intact TPTX
component of the P-450 enzyme system in proximal tubules and
glomeruli [16].
To specifically define the localization of 24-hydroxylase, we
measured the 24-hydroxylase activity in isolated single nephron
segments. Our data show that the enzyme activity was detect-
able only in the PCT of vitamin D-replete rats and none in any
other segments of vitamin D deficient or replete rats [13]. These
data may seem to support Ghazarian's proposal that these two
enzyme activities can be catalyzed by a single enzyme system.
However, we have shown that with administration of
1 ,25(OH)2D3, 24-hydroxylase is induced not only in the PCT but
also in the PST [13]. Moreover, recently Ichikawa, Hiwatashi,
and Nishii [17] demonstrated the presence of an immunologi-
cally distinct enzyme for l-hydroxylase, suggesting these two
enzyme activities may be catalyzed by a different enzyme
system.
Regulation of 1-hydroxylase
Parathyroid hormone (PTH). It has been established that
PTH stimulates 1-hydroxylase activity and enhances renal
production of l,25(OH)2D [12, 13, 18—21]. Several lines of
evidence indicate that the secondary hyperparathyroidism
plays an important role in 1 -hydroxylase activation in vitamin D
deficiency [13, 21]: Parathyrdoidectomy largely (—70 to 80%)
abolishes the 1-hydroxylase activity in vitamin D deficiency and
administration of PTH to thyroparapathyroidectomized (TPTX)
vitamin D deficient rats restores the reduced enzyme activity to
the level seen in the vitamin D deficient animal with intact
parathyroid glands (Figs. 1 and 2). It is of interest that the
maximum 1-hydroxylase activity obtained by PTH administra-
tion to parathyroidectomized (PTX) vitamin D deficient rats
does not exceed the enzyme activity of vitamin D deficient rats
with intact parathyroid glands. Moreover, exogenous PTH and
cyclic AMP given to vitamin D deficient rats with intact
parathyroid glands did not further increase the 1-hydroxylase in
the PCT (Fig. 2). These observations support the notion that the
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Fig. 2. Effect of PTH and cyclic AMP on the 1-hydroxylase activity of
the PCT and PST of intact and TPTX-vitamin D-deficient rats. Twenty-
four hours after sham or TPTX, rats were given 50 U 1—34 bovine PTH
(dotted columns), 20 j/mole cyclic AMP (shaded columns), or vehicle
(open columns) every 2 hr s.c. Two hours after the fourth injection, rats
were sacrificed and l-hydroxylase was assayed in PCT and PST. Note
that both PTH and cyclic AMP did not affect 1-hydroxylase activity in
the PTH and cyclic AMP did not affect 1-hydroxylase activity in the
PCT of vitamin D-deficient rats with intact parathyroid glands. In
contrast, both PTH and cyclic AMP restored the reduced enzyme
activity in the PCT of TPTX rats to the level of intact rats. Both PTH
and cyclic AMP did not stimulate l-hydroxylase in the PST. ND means
not detectable. (Reproduced from [12] with permission.)
1-hydroxylase activity in the PCT of vitamin D deficiency is
stimulated maximally by the secondary hyperparathyroidism.
The addition of PTH to kidney cells in vitro stimulates
conversion of 25(OH)D3 to 1 ,25(OH)2D3 in a variety of prepa-
rations from several animal species [18, 22—28]. In the primary
culture of chick kidney, stimulation of 1-hydroxylase by PTH
requires the presence of insulin [29]; this stimulation needs
several hours to appear both in vivo [30] and in vitro [31]. The
in vivo effect is blocked by cycloheximide [30]. These results
suggest that some new enzyme protein synthesis is involved in
1-hydroxylase activation by PTH. However, conflicting obser-
vations report the following: Rasmussen et al [18] demonstrated
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Intactthat incubation of isolated chick tubules with the presence of
PTH or cyclic AMP for 15 mm caused a significant increase of
l,25(OH)2D1 production. Larkins et a! [22] also demonstrated
similar effects of cyclic AMP in a similar chick tubule prepara-
tion, but this effect was not blocked by cycloheximide. Rost,
Bikle, and Kaplan [28] demonstrated that PTH stimulates
1-hydroxylase in vitamin D-deficient chick kidney slices within
30 mm. Thus, it seems that there may be two mechanisms of
PTH dependent 1-hydroxylase stimulation: One is rapid appear-
ing within minutes and does not need protein synthesis; another
requires several hours and does involve new protein synthesis.
That the stimulatory effect of PTH is likely to be mediated by
cyclic AMP is provided by the following observations: Cyclic
AMP stimulates 1,25(OH)2D3 production when added to iso-
lated chick renal tubules and primary cell culture systems [22,
23, 27, 281. Similar enzyme stimulation has been demonstrated
in vivo by constant infusion of cyclic AMP into TPTX vitamin
D-deficient rats [21]. The magnitude and time course of stimu-
lation of I ,25(OH)2D production by cyclic AMP were compa-
rable to those of PTH [211. Our recent data show that
exogenous cyclic AMP restores the reduced 1-hydroxylase in
PCT of TPTX vitamin D-deficient rats [32]. In addition, the
effects of PTH and cyclic AMP are not additive [21], suggesting
that both agents act on the same target cells and the effect of
PTH is mediated by cyclic AMP. The presence of PTJ-I-
sensitive adenylate cyclase together with the 1-hydroxylase in
the PCT of the rat kidney is consistent with the thesis.
Calcitonin. The effects of calcitonin on 1-hydroxylase have
been controversial. Galante et al [33] first demonstrated that
calcitonin injected subcutaneously every 6 hr for 48 hr stimu-
lates the I ,25(OH),D3 production in vitamin-D deficient rats.
Larkins, MacAuley, and Maclntyre [34] also demonstrated in
vitro stimulation by calcitonin of 1-hydroxylase in isolated
tubules from vitamin D-deficient chick kidney. By contrast,
Lorenc et al [351 reported that the in vivo stimulation by
calcitonin of I ,25(OH)1D3 production in vitamin D-deficient rats
was abolished by TPTX claiming that the stimulatory effect is
secondary to an increase in PTH secretion due to a probable
further decline in serum calcium. This is rather unlikely based
on the results of Horiuchi et al [21] and ourselves [321 as already
discussed, that is, that 1-hydroxylase is stimulated maximally
by endogenous PTH in vitamin D deficiency and that injection
of exogenous PTH or cyclic AMP in vitamin-D deficient rats
with intact parathyroid glands failed to enhance I ,25(OH)2D1
production. Furthermore, Horiuchi et al [36] demonstrated that
calcitonin infused in vivo in TPTX vitamin D-deficient rats
stimulated I ,25(OH)2D3 production, an observation contrary to
those of Lorenc et al [35].
The exclusive localization of the 1-hydroxylase in the PCTof
mature vitamin D-deficient rats [13] is similar to that seen in the
rachitic chick where the enzyme is localized in the PCT and
cortical thick loops (considered to be an extension of PCT) [9].
However, our data obtained in the rat kidney are somewhat
different from those of Akiba et al [II] who showed that both
the PCT and PST are the sites of 1-hydroxylation in the fetal
rabbit kidney. The lack of the enzyme activity in the PST of
mature vitamin-D deficient rats but its presence in the fetal
rabbit kidney may seem puzzling, possibly due to the species
difference or the ontogeny of the enzyme activity. It is possible
that the distribution of the 1-hydroxylase may change depend-
TPTX
0.8
0
0.4
0 _
PCT PST PCT PST
Fig. 3. Effect of calcitonin on the I-hydroxylase activity of the PCT and
PSTof vitamin D-deficient rats without (intact) or with TPTX. Note that
calcitonin stimulates 1-hydroxylase in the PST but not in the PCT in
both intact and TPTX animals. Open and closed bars represent the
enzyme activity in vehicle and calcitonin-treated rats, respectively. ND
means not detectable. (Reproduced from [12] with permission.)
ing on the developmental stage of the animal (the ontogeny) and
a greater demand for I ,25(OH)2D3 may be met under certain
circumstances, such as in the fetus, by recruiting a larger
portion of the tubule, that is, PCT plus PST, producing
I ,25(OH)2D3. If this is the case, the factor(s) which regulates
the ontogeny of 1-hydroxylase should be identified.
It has been shown that both PTH and calcitonin, when given
in vivo, can stimulate the production of l,25(OH)2D3 from
25(OH)D3 in TPTX vitamin D-deficient rats [211. Moreover, the
in vivo effects of PTH and calcitonin are additive [361, a finding
suggestive of different sites of action of these two hormones. In
addition, plasma calcitonin levels are known to be elevated in
the fetus of several mammalian species [37—40], while they are
likely to be low in vitamin D-deficient rats due to hypocalcemia.
These observations suggested to us that calcitonin could be the
hormone-stimulating enzyme activity in the PST while PTH is
primarily responsible for 1-hydroxylase activation. Such a
postulate explains the presence of 1-hydroxylase in the PST of
the fetal kidney but not in the PST of the mature vitamin
D-deficient rat.
This hypothesis was tested by measuring 1-hydroxylase
activity of nephron segments vitamin D-deficient rats given
calcitonin [41]. As depicted in Fig. 3, the administration of
calcitonin to vitamin D-deficient rats with or without TPTX
stimulated 1-hydroxylase activity in the PST but did not affect
the enzyme activity in the PCT. The enzyme activity remained
undetectable in other nephron segments, including glomeruli,
medullary and cortical thick ascending limbs of Henle, distal
convoluted tubules, and collecting tubules. These data clearly
showed that calcitonin selectively stimulates 1-hydroxylase in
the PST and that calcitonin and PTH act on anatomically and
functionally distinct segments of the nephron. These results
explain the presence of 1-hydroxylase in the PST of the fetal
kidney and its absence in the PST of the mature vitamin
D-deficient rat. These data agree with in vivo observations that
calcitonin stimulates the l-hydroxy!ase activity independent of
PTH and that the effects of PTH and calcitonin are additive [30,
36].
As mentioned above, PTH is believed to stimulate 1-hydrox-
ylase via adenylate cyclase stimulation. By contrast, calcitonin
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does not stimulate adenylate cyclase in the PST [41]. These data
strongly suggest that calcitonin stimulates 1-hydroxylase in the
PST via mechanisms independent of cyclic AMP. It is impor-
tant to note that the administration of either PTH or cyclic AMP
to vitamin D-deficient rats with or without TPTX did not
stimulate 1-hydroxylase in the PST [32]. Thus, it is evident that
the 1-hydroxylase in the PST is insensitive to cyclic AMP as
well as to PTH.
To define the mechanism of calcitonin action, we have
recently established a primary culture system of rat kidney and
showed that calcitonin stimulates 1-hydroxylase activity when
added to culture plates [25], Similar results have been reported
in the primary culture of mouse [42] and chick [22] kidney.
These data indicate that calcitonin directly acts in the kidney.
Matsumoto et al [43] recently reported that prostaglandin E2
(PGE2) antagonized the stimulatory effect of calcitonin on
1-hydroxylase when both agents are infused into TPTX vitamin
D-deficient rats. However, in our primary culture system of rat
kidney cells, we could not detect any effect of PGE2 on the
action of calcitonin, although PGE2 did stimulate adenylate
cyclase activity in this system, suggesting that the inhibitory
effect of PGE2 on the action of calcitonin might be indirect
(unpublished data). Recent studies demonstrate that there are at
least four intracellular messengers for action of peptide hor-
mones, that is, cyclic AMP, cyclic GMP, calcium, and inositol-
triphosphate. It is possible that calcium, inositol-triphosphate,
or cyclic GMP might be involved in the action of calcitonin on
the 1-hydroxylase in the PST. Recently, it has been reported
that both human and salmon calcitonin stimulated cyclic GMP
accumulation in human kidney cortical cells [44]. Further
studies are needed to elucidate the mechanism of calcitonin in
1-hydroxylase activation.
The studies using microdissected single nephron segments
revealed the presence of two distinct 1-hydroxylase systems in
the kidney. One is localized in the PCT stimulated by PTH via
cyclic AMP and thus activated in vitamin D deficiency: The
other is in the PST, insensitive to PTH and cyclic AMP, thus
latent in vitamin D deficiency, and stimulated by calcitonin via
cyclic AMP-independent mechanisms (Fig. 4)145, 46].
While the role of the PTH-sensitive l-hydroxylase in the PCT
in calcium metabolism has been well established, the biological
significance of calcitonin-sensitive 1-hydroxylase may not be
apparent. The thesis that the kidney is the sole organ endowed
with the 1-hydroxylase has been based on data obtained in
vitamin D-deficient animals in which the calcitonin-sensitive
1-hydroxylase is obviously latent. Thus, the discovery of I-
hydroxylase sensitive to calcitonin in the PST raises the possi-
bility of the presence of 1-hydroxylase in tissues other than the
kidney. Such 1-hydroxylase may be specifically responsive to
calcitonin and latent in vitamin D deficiency. Recent evidence
suggests 1 ,25(OH)2D3 synthesis by the placenta and/or fetal
tissues [47, 48], cultured bone cells [49, 50], and alveolar
macrophages from patients with sarcoidosis [51]. It has yet to
be shown whether these extrarenal 1-hydroxylases are sensitive
to calcitonin.
The possible physiological significance of calcitonin sensitive
1-hydroxylase can be contemplated. In the fetus, serum ionized
calcium concentrations are elevated, needing l,25(OH)2D3 to
develop the skeleton. Were the fetus not endowed with the
calcitonin-sensitive 1-hydroxylase, it might not be able to
Proximal convoluted tubules (PCT)
recruit sufficient amounts of I ,25(OH)2D3 because hypercal-
cemia may suppress PTH secretion while stimulating calcitonin
secretion. Calcitonin is a hormone evolutionally older than PTH
and one can postulate that the calcitonin-sensitive 1-hydrox-
ylase may be important in a primitive life form or stage of life
such as the fetus. Moreover, elevated plasma 1 ,25(OH)2D3
levels during pregnancy [52] may be explained in part by high
circulating calcitonin levels which may stimulate 1-hydroxylase
in the placenta and the PST. These postulates, which have
evolved from studies on nephron heterogeneity, certainly re-
quire further investigation.
Hydrogen ion concentration. Metabolic acidosis may alter
vitamin D metabolism and may underlie metabolic bone dis-
eases seen in patients with chronic metabolic acidosis. In both
vitamin D-deficient rats [53] and chicks [54] with metabolic
acidosis induced by ammonium chloride, in vivo conversion of
3H-25(OH)D3 to 3H-l ,25(OH)2D3 was suppressed. Also, the
chick kidney 1-hydroxylase activity measured in vitro was
diminished in acidosis [54, 55]. We also demonstrated that
metabolic acidosis markedly suppressed the 1-hydroxylase in
the PCT in vitamin D-deficient rats [56]. However, 16 hr of
acidosis did not alter the enzyme activity [56].
In experiments with isolated renal tubules from the vitamin
D-deficient chick, the reduction of pH to less than 7.0 reduced
the enzyme activity [57]. In mitochondrial preparations from
the chick kidney, the optimum pH for 1-hydroxylase activity is
reported to be either 7.4 [58] or 6.9 [59]. We showed that the
reduction in the pH of the incubation medium from 7.4 to 7.0
did not affect the enzyme activity in the PCT of vitamin
D-deficient rats [56]. Lowering the perfusate pH from 7.4 to 7.1
does not affect 1-hydroxylase activity in the isolated perfused
Proximal straight tubules (PST)
Fig. 4. Model of two distinct 1-hydroxylase systems in the mammalian
kidney. (Reproduced from [121 with permission.)
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rat kidney [60]. Thus, the suppression of the enzyme by
acidosis does not seem to be due to a direct effect of low pH.
The mechanism responsible for suppression of 1-hydroxylase
in metabolic acidosis remains unclear. As described above,
PCT is the site of the elevated 1-hydroxylase in vitamin
D-deficient rats, and this enzyme activity is regulated by PTH
via cyclic AMP. Therefore, the suppression of 1-hydroxylase in
the PCT of acidotic vitamin D-deficient rats could be due either
to inhibition of PTH secretion or renal resistance to the action
of PTH. Further, renal resistance to PTH action in the PCT
could be at the step of PTH-dependent cyclic AMP generation
or at steps beyond cyclic AMP production. A study from our
laboratory showed that the excess PTH did not stimulate the
suppressed 1-hydroxylase in the PCT of acidotic rats, but cyclic
AMP fully restored the enzyme activity to normal [56]. These
data strongly suggest that metabolic acidosis suppresses 1-
hydroxylase activity in the PCT by inhibiting PTH-dependent
adenylate cyclase activation. Moreover, the data indicate that
metabolic acidosis does not affect the intracellular processes
necessary for the 1-hydroxylase stimulation following cyclic
AMP formation.
In addition, calcitonin stimulates the 1-hydroxylase activity
of the PST of acidotic rats to levels similar to those observed in
control rats treated with calcitonin [56]. These results show that
the cyclic AMP-independent mechanisms in the PST stimulat-
ing 1-hydroxylase are not affected in metabolic acidosis.
Effects of vitamin D in the kidney
Phosphate handling. The vitamin D role in the renal handling
of Pi has remained obscure due to conflicting results. Support
for a stimulatory effect of vitamin D on renal Pi transport
derives from clearance and micropuncture studies [61-.64] de-
scribing the effects of vitamin D analogs in pharmacologic
doses. Popovtzer et al [61], Pushchett, Moronz, and Kurnick
[63] and Pushchett et al [62] have reported stimulation of Pi
reabsorption by 1 ,25(OH)2D3 which required the presence of
PTH. Utilizing much lower doses of l,25(OH)2D3 in vitamin
D-deflcient TPTX rats small doses of PTH stimulate renal P1
reabsorption [65, 66]. Liang et al [67] and Bonjour, Preston, and
Fleisch [68] have studied the effects of 1 ,25(OH)2D3 on Pi
uptake into renal cells isolated from rachitic chicks. Following
in vivo administration of pharmacologic doses of 1 ,25(OH)2D3,
P1 uptake into tubule cells isolated increased after 3 hr, but it
decreased in the cells isolated 17 hr after 1 ,25(OH)2D3. They
attributed the initial increase in Pi uptake to 1 ,25(OH)2D3 and
the later decrease in P1 uptake to an increase in the Pi load
presented to the kidney in vivo [68]. They also showed
1 ,25(0H2D3 added in vitro stimulates Pi uptake into renal tubule
cells isolated from rachitic chicks [68]. Stimulation of Pi uptake
was detectable with as little as 10—14 M 1 ,25(OH)2D3, and was
blocked by cycloheximide and actinomycin D. The effect of
1 ,25(OH)2D3 peaked at 2 hr due to an increase in the Vm of P1
uptake. These results were most consistent with a genomic
mechanism of action of 1 ,25(OH)2D3 on Pi transport [68].
Inhibition of Pi transport by 1 ,25(OH)2D3 has been reported
in a series of studies [69—721. The doses of 1 ,25(OH)2D3 used in
these studies were 120 pmoles iv once or 26 pmoles/day ip for 11
days, the doses required to normalize intestinal calcium and Pi
absorption in TPTX rats [73], thus considered to be physiolog-
ical. They assessed and compared Pi excretion during P1
infusion and Na-dependent Pi uptake into brushborder mem-
brane vesicles (BBMV) isolated from the renal cortex [71].
Their data show that 1 ,25(OH)2D3 decreases renal tubular Pi
reabsorption and suggest that a functional role of 1,25(OH)2D3
might maintain the tubular capacity to respond to a Pi load.
The reasons for these conflicting results on the effect of
1,25(OH)2D3 on renal P1 transport are unclear. Several factors
may have contributed. Some studies were performed in vitamin
D-repleted animals in which the effects of vitamin D adminis-
tration may differ from those in vitamin D-deficient animals. In
addition, in studies utilizing vitamin D-deficient animals,
rachitogenic diets, low in calcium and phosphorus content,
produce hypocalcemia, hypophosphatemia, and secondary
hyperparathyroidism, all of which may affect tubular Pi han-
dling independent of vitamin D [74]. Kurnik and Hruska [75]
developed a normocalcemic, normophosphatemic model of
mild vitamin D depletion in rats which shows little evidence of
secondary hyperparathyroidism. Using this model, they exam-
ined the effects of vitamin D depletion and repletion with
1 ,25(OH)2D3 on P1 transport in the brushborder membrane
vesicle (BBMV). Partially vitamin D-deficient (PVDD) rats had
increased Pi excretion, both absolute and fractional terms with
a decrease in Na-dependent Pi uptake in BBMV. Administra-
tion of 1 ,25(OH)2D3 to PVDD rats (15 pmoles/100 g body wt) 24
hr prior to the study decreased fractional excretion of Pi to the
level of normal rats with an increase in Na-dependent Pi
transport in BBMV. Larger doses of 1 ,25(OH)2D3 produced
hypercalcemia and hyperphosphatemia, an increase in P1 excre-
tion, and a blunted response of P1 transport to 1 ,25(OH)2D3.
These latter data may partially explain the inhibitory effects of
1 ,25(OH)D3 reported in studies in which plasma Pi was not
controlled and larger doses of 1,25(OH)2D3 were used. These
studies clearly demonstrated that vitamin D depletion is asso-
ciated with decreased Pi reabsorption that is corrected rapidly
by physiologic amounts of 1 ,25(OH)2D3. The stimulatory effect
of 1 ,25(OH)2D3 on Pi transport is manifest at the level of the
Na-dependent Pi transport in the brushborder membrane of
proximal tubule cells.
Calcium handling. It has not been clear whether vitamin D,
or one or more of its metabolites, exerts a direct effect on the
renal tubular transport of calcium. Studies in humans as well as
in experimental animals demonstrated that vitamin D has a
hypocalciunc effect [76, 77], a calciuric effect [78, 791, or no
effect at all [80—82]. These differing conclusions appear to arise
from several reasons: the difference in the vitamin D status of
the animals [77, 80], the difference in the doses and the kinds of
vitamin D metabolites administered [77, 80], the changes in the
serum calcium concentration and the filtered load of calcium
[83], and the difference in the status of the function of PTH [781,
a hormone that has a direct action on the renal tubular calcium
reabsorption in the distal nephron [84—881. Because one or more
of these factors was not controlled or considered in many
studies, it is often difficult to determine whether or not vitamin
D has any direct action on the renal tubular transport of
calcium.
In an attempt to critically examine this question, Yamamoto
et al [88] have investigated the renal handling of calcium in rats
in which the vitamin D status, the PTH status, and the serum
calcium concentration were controlled independently. The ap-
parent threshold of calcium excretion in vitamin D-deficient,
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Fig. 5. Effects of PTH infusion on the renal handling of calcium among
three groups of TPTX rats. Group A was fed a vitamin D-deficient
normal calcium diet, group B a vitamin D-deficient high calcium diet,
and group C a vitamin D-repleted diet. In groups A and B, PTH was
given at 2.5 U/hr (•) and in group C at 0.75 U/hr (0). Renal calcium
reabsorption is augmented or shifted to the right with P'FH. However,
a greater dose of P1'H was required in vitamin D deficient rats (groups
A and B) for a comparable shift in calcium reabsorption. Also, calcium
threshold is lower in vitamin D deficiency with (group A) or without
secondary hyperparathyroidism (group B) than in the vitamin D-
repleted group (group C). (Reproduced from [88] with permission.)
TP'TX rats was lower as compared with that in the vitamin
D-repleted rat regardless of the presence of preceding hyper-
parathyroidism. PTH infused at 0.75 U/hr represents an esti-
mated secretion rate of the hormone in vitamin D-repleted rat;
the threshold of calcium excretion increased from 1.5 to 2.1 mM
in vitamin D-repleted rats, while it was unchanged in vitamin
D-deficient rats. A higher dose of PTH, 2.5 U/hr, an estimated
secretion rate in vitamin D-deficient rat with secondary hyper-
parathyroidism, increased renal calcium threshold in vitamin
D-deficient rats approximately by a similar magnitude from 1.0
to 1.6 mri (Fig. 5). The increase in the threshold in vitamin
D-deficient rats was the same irrespective of the presence of
preceding hyperparathyroidism. These data demonstrate that
vitamin D deficiency decreases the effect of PTH to stimulate
tubular calcium reabsorption both in the absence or presence of
preceding hyperparathyroidism and that the vitamin D defi-
ciency, per se, decreases tubular reabsorption of calcium [891.
Furthermore, they demonstrated that 1 ,25(OH)2D3, but not
24,25(OH)2D3, stimulates renal tubular calcium reabsorption
(personal communication). These results clearly demonstrate
evidence for a stimulatory effect of l,25(OH)2D3 on renal
tubular calcium reabsorption.
Although the exact site of action of vitamin D on tubular
calcium reabsorption remains to be determined, it is tempting to
postulate that 1 ,25(OH)2D3 may enhance the responsiveness of
tubule to PTH at the cortical thick ascending loop of Henle
and/or connecting tubules where the effect of PTH on tubular
calcium transport has been reported [84—86, 88]
Localization of receptors for 1,25(OH)2D3 (Table 2)
The mechanism of action of 1 ,25(OH)2D3 involves binding of
this hormone to cytoplasmic receptors and migration of the
sterol-receptor complex to the nucleus leading to the induction
of hormone-specific protein synthesis [1—4]. Recent studies
demonstrated the presence of receptors for 1 ,25(OH)2D3 in the
kidney of mouse [90], rat [91], and chick [921, as well as the
nuclear transfer of the 1 ,25(OH)2D3-receptor complex in mouse
Nephron
segments Enzymes CaBP
Receptors
Autoradiography Direct assay
Gim + — + Not tested
PCT + — — +
PST + — — Not tested
MTAL - - + +
CTAL — Not tested
DCT — + + Not tested
CNT — + + Not tested
CCT — — Not tested
MCT — — — —
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kidney [93]. It is also well established that at least two distinct
proteins, that is, 24-hydroxylase and calcium-binding protein
(CaBP), are induced by l,25(OH)2D3 in the kidney [1—4].
Recent autoradiographic data demonstrated that the nuclear
uptake of l,25(OH)2[3HJD3 in the kidney is localized predomi-
nantly in the distal nephron including medullary and cortical
thick ascending limb of Henle (MTAL and CTAL), distal
convoluted tubules (DCT), and, to some extent, in the
glomerulus [94]. These data are consistent with findings of the
exclusive localization of vitamin D-dependent CaBP in the
distal nephron by immunohistochemical methods in the kidneys
of mouse [95], rat [96—98], human [95, 96], rabbit [98], and chick
[95, 98, 99]. Another protein induced by l,25(OH)2D3, 24-
hydroxylase, has been localized exclusively in the proximal
nephron [131. Therefore, is seems reasonable that either recep-
tor for l,25(OH)2D3 or another mechanism to recognize
1 ,25(OH)2D3 must be present in the proximal nephron to
transfer the hormonal signal to the site of protein synthesis. We
examined this possibility using defined single nephron segments
and demonstrated that the receptors for 1 ,25(OH)2D3 are indeed
localized both in proximal nephron (PCT) and distal nephron
(MTAL) [100].
Vitamin D-dependent calcium binding protein. To our knowl-
edge, Taylor and Wasserman [100] first demonstrated the
presence of vitamin D-dependent CaBP in chick kidney.
Christakos and Norman [101] reported that the vitamin D-
dependent increase in chick kidney CaBP is accompanied by a
parallel increase in the amount of mRNA coded for CaBP.
Morrissey et al [94] were the first to localize CaBP in the kidney
using immunohistological techniques with rabbit antibody
against human renal CaBP. Their data showed that CaBP
localizes in the distal tubule, collecting ducts, and the ascending
loop of Henle in the human, dog, cat, rat, mouse, and chick
kidney [95]. Christakos, Brunette, and Norman [98], using a
radioimmunoassay with antisera prepared against vitamin D-
dependent CaBP of the chick and microdissected single neph-
ron segments of the chick kidney, showed that CaBP is local-
ized in distal convoluted tubules (DCT), cortical collecting
tubules, and thin loops of Henle. Rothen and Christakos [96]
demonstrated, using rabbit antisera raised against chick CaBP,
that CaBP is localized in DCT, the initial part of collecting
tubules and in a lesser amount in the outer medullary collecting
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Table 2. Distribution of vitamin D metabolizing enzymes, vitamin
D-dependent calcium binding protein and receptors for I ,25(OH)2D3
along the rat nephron
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duct in both human and rat kidneys. CaBP immunoreactive
sites were found throughout the cytosol and the nuclear
euchromatin, No preferential labeling of cellular membranes
was found [961, suggesting CaBP may involve in regulating
intracellular calcium, but not in the initial transmembrane
transport of calcium [961. Most recently, Taylor, Mcintosh, and
Bourdeau [97] reported using sheep anti-chick intestinal CaBP
antisera that CaBP is localized in DCT, connecting tubules
(CNT), and collecting tubules (the latter two have less amounts
of CaBP) in rabbit kidney, DCT, CNT, and in a lesser amount
in collecting tubules of rat kidney and exclusively in DCT in
chick kidney [981.
Taken together, these data suggest that vitamin D-dependent
CaBP is localized mostly in DCT, CNT, and a part of collecting
tubules in all mammalian and chick kidneys, which agrees with
the localization of receptors for I ,25(OH)2D3 in these segments
[94].
Induction of vitamin D metabolizing enzymes by I ,25(OHjD3
and its localization. Another protein known to be induced by
l,25(OH)2D3 is the 24-hydroxylase. As described above, this
enzyme is localized exclusively in the PCT of normal vitamin
D-repleted rat kidneys. In contrast to the optimal in vivo
condition for 1-hydroxylase activation in vitamin D deficiency,
the lack of significant 24-hydroxylase activity does not neces-
sarily rule out the presence of the enzyme in nephron segments
other than the PCT. It is possible that enzyme activity may
become manifest in other segments under stimulated condi-
tions. Indeed, when 24-hydroxylase activity was measured in
rats given I ,25(OH)2D3, a most potent inducer of 24-hydrox-
ylase [102, 1031, the enzyme activity not only increased two- to
threefold in the PCT but also became evident in the PST [13],
with the specific activity of the enzyme becoming even higher in
the PST than in the PCT [13]. No significant 24-hydroxylase
activity was found in any other segments of the nephron even in
l,25(OH)2D3-treated vitamin D-repleted rats [13]. It is reason-
able to assume that this action of l,25(OH)2D3 to induce
24-hydroxylase is mediated by specific receptors; such
l,25(OH)2D3 receptors should be localized in the proximal
tubules. Indeed, as discussed above, we demonstrated the
presence of the receptor for 1 ,25(OH)2D3 in the PCT as well as
in the MTAL [100].
Several other 25-hydroxyvitamin D metabolites have been
reported to be produced by the kidney; this production may be
stimulated by l,25(OH)2D. While the receptors for
1,25(OH)2D3 are also found in the CTAL and MTAL [100],
proteins induced by 1,25(OH)2D3 in these nephron segments
have not been identified. It is possible, therefore, that one or
more enzymes responsible for the production of other metabo-
lites of vitamin D are localized in these nephron segments. To
test these possibilities, we examined metabolism of 25(OH)2D3
and 24,25(OH)2[3H]D3 using mitochondrial preparations and
microdissected single nephron segments of rats treated with
1,25(OH)2D3 [104, 105].
When mitochondria from I ,25(OH)2D3-treated rat kidneys
were incubated with 25(OH)D3, three major peaks were identi-
fied using LH-20 column chromatography. Two of them were
identified as 24,25(OH)2D3 and 24-oxo-25(OH)D3, respectively,
based on their chromatographic behaviors and chemical and
spectroscopic features [104, 1051. Another peak has not yet
been characterized fully, but it seems to be a lactone derivative
based on its chromatographic behavior [1051
When the similarly prepared mitochondria were incubated
with 24,25(OH)2[3H]D3, 24-oxo-25(OI-I)D3, and the unidentified
metabolite described above were also produced [104, 105]. To
localize metabolite production sites, we first incubated
mitochondria from renal cortex and medulla separately with
either 25(OH)[3H]D3. Cortical mitochondria produced all three
metabolites, while medullary mitochondria failed to produce
any of them, indicating that the enzymes are localized in the
cortex. When metabolism of I ,25(OH),{3H]D1 and 24,25(OH)2-
[3H]D was examined using microdissected single nephron in
the cortex, three metabolites are produced by both PCT and
PST, but no significant amount of these metabolites was pro-
duced by any other nephron segments including glomeruli
MTAL, CTAL, DCT, CNT, and CCT from either substrate
[105]. These data are consistent with our earlier report that
24-hydroxylase is localized exclusively in the PCT and PST
[13]. Furthermore, these data clearly demonstrate that 24-oxo-
25(OH)D3 and another unidentified metabolite are also pro-
duced in the PCT and PST. In addition, two minor metabolites
were produced in both segments suggesting that enzymes
responsible for the production of these additional minor metab-
olites may not be present in mitochondria but rather in other
subcellular fractions such as microsome. Microsomal produc-
tion of 25,26(OH)2D3 has been reported [106]. The elution
profile of 25,26(OH)2D1 is similar to one of these two minor
metabolites.
Although further characterization of these unidentified
metabolites is needed, our data clearly demonstrate the local-
ization of at least five different enzyme activities of vitamin D
metabolism, including those responsible for the production of
24,25(OFI)2D3 and 24-oxo-25(OH)2D3 which are in the PCT and
PST.
Mechanism of action of I ,25(OH)2D3 in the kidney
It is widely recognized that steroid hormones act on target
cells by a mechanism involving several specific steps: binding of
the hormone to a cytosolic receptor, translocation of the
hormone-receptor complex to the nucleus, and finally induction
of protein synthesis. It is thought that I ,25(OH)2D3 stimulates
the synthesis of a specific CaBP in the intestine via this genomic
mechanism [1—4]. 1,25(OH)2D3 stimulates calcium reabsorption
and also enhances the sensitivity to PTH to stimulate the
tubular reabsorption of calcium [431. Although the exact sites
for this effect of l,25(OH)2D3 are unclear, it is tempting to
propose that these sites are the CTAL [84—86], DCT [87], CNT
[88], or all of these segments where PTH stimulates calcium
transport. 1 ,25(OH)2D3 alone can also stimulate tubular reab-
sorption of calcium in the kidney [43]. These actions of
1,25(OH)2D3 seem to require new protein synthesis perhaps
CaBP, since the response cannot be observed until several
hours after the administration of I ,25(OH)2D3, suggesting that
this effect of vitamin D also involves genomic mechanism.
As mentioned earlier, I ,25(OH)2D3 stimulates Pi uptake by
the BBMV of proximal tubules which can be inhibited by
actinomycin D or cycloheximide. These results, taken together
with the presence of receptors for 1 ,25(OH)2D3 in the proximal
tubules, suggest I ,25(OH)2D3 may affect Pi transport via a
genomic mechanism. Also, the enzymes responsible for the
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production of several metabolites of vitamin D are induced by
1,25(OH)2D3 and localized in the proximal nephron [13, 104,
105] as described above; these effects may involve a genomic
mechanism. It is unclear at present what a receptor role is for
1 ,25(OH)2D3 in the MTAL because no protein has been identi-
fied which can be induced by 1 ,25(OH)2D3 in this nephron
segment.
Although a genomic mechanism is probably the major mech-
anism by which l,25(OH)2D3 exerts its effects in the kidney,
nongenomic mechanisms may be involved in expression of
some effects of 1 ,25(OH)2D3. Edelman et al [107] reported that
1,25(OH)2D3 elicited a change in cell membrane potential (Vm)
within 1 mm in proximal tubular cells of the necturus kidney
whether it is injected in the lumen or peritubular capillaries. A
similar quick action of 1 ,25(OH)2D3 has been reported in the
intestine: 1,25(OH)2D3 increases the phosphatidyicholine con-
tent of the BBMV [108] and calcium uptake by BBMV within
minutes [109]. These data clearly indicate that there is a
nongenomic mechanism by which 1 ,25(OH)2D3 affects trans-
port function of these organs. Whether or not a receptor-
mediated mechanism is involved in the changes of the Vm in the
proximal tubules is unknown and needs further study.
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